BSX BOSTON SCIENTIFIC CORP Insider Trading

Director Cheryl Pegus purchases initial 1,770 shares of BSX at $56.49 for $99,987.30

Director Cheryl Pegus acquired her first position in Boston Scientific, purchasing 1,770 shares at $56.49 on 2026-05-20 for a total value of $99,987.30. The purchase occurs near the lower end of the 52-week range ($52.52–$109.50), with the stock currently down 47.8% from its 52-week high and down 4.0% over 30 days and 23.4% over 90 days. Boston Scientific reported strong fundamentals with $5.2B quarterly revenue, $1.3B net income, and 19.9% annual revenue growth, though the stock trades at a P/E of 23.91. This initiation of a director position during a period of weakness merits monitoring to determine whether subsequent transactions establish a pattern of accumulation or represent a one-time addition to holdings.

Director Edward J Ludwig buys 3,580 shares of BSX at $56.68; stock -47.8% from 52-week high. Cluster pattern: 2 other insiders also bought within 14 days.

Edward J Ludwig, a Director, purchased 3,580 shares at $56.68 on 2026-05-20, increasing his holdings from 21,779 to 25,359 shares. This transaction coincides with a cluster buy signal: 2 other insiders have also purchased within the past 14 days. The stock is currently trading at $57.15, down 47.8% from its 52-week high of $109.50 and down 23.4% over the past 90 days. Ludwig's cross-ticker track record shows 2 prior buys with an average 90-day return of +12.0% and a 100.00% win rate, though his single prior sale at BSX on 2025-02-11 was well-timed with a 90-day return of -2.5%. The fundamental backdrop shows strong quarterly net income of $1,339,000,000.00 and annual revenue growth of +19.9%, though the P/E of 23.91 reflects market valuation pressures.

Director David C Habiger purchased 4,450 shares at Boston Scientific for $251,098.10 across two days, raising holdings +47.2%.

David C Habiger, a Director at Boston Scientific, executed two separate purchases totaling 4,450 shares for $251,098.10 on 2026-05-19 and 2026-05-20 at prices of $56.95 and $55.92 respectively, with a blended average of $56.43. This transaction increased his holdings from 9,428 shares to 13,878 shares, representing a +47.2% increase in his position. The current stock price of $57.15 is -47.8% from the 52-week high of $109.50 and down -23.4% over the past 90 days, placing this purchase within a period of significant price decline. Across his cross-ticker trade history, Habiger's prior six open-market buys show an average 90-day return of +6.2% with a 33.33% win rate, providing limited historical precedent for assessing whether this particular purchase will prove well-positioned.

BSX Chairman/CEO Mahoney sells 160,901 shares for $15.0M under pre-arranged 10b5-1 plan adopted 2025-08-29

Michael F. Mahoney, Chairman, President & CEO of Boston Scientific, executed 2 separate sales totaling 160,901 shares for $15,043,394.38 at blended average price of $93.49 on 2026-02-02. This transaction reduces his holdings from 1,572,636 to 1,411,735 shares, a net reduction of 10.2% from pre-transaction levels. The sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-29, meaning this is a scheduled, non-discretionary transaction executed under a pre-established schedule and price framework. Since the trade is governed by a 10b5-1 plan, it represents prearranged capital management rather than a discretionary market timing decision by the executive. The magnitude of the sale and the executive's continued substantial ownership post-transaction warrant review of BSX's broader capital allocation strategy and any disclosed business developments.

EVP Arthur C Butcher sold 17,313 shares at $101.55 for $1.8M, reducing BSX holdings 42.3%; stock down 8.4% from 52-week high.

Butcher, serving as EVP and Group President of MedSurg & APAC, sold 17,313 shares (17.3K shares) at $101.55 on 2025-12-01, bringing his post-transaction holdings to 23,600 shares (23.6K shares) from 40,913 shares (40.9K shares) — a net reduction of 42.3%. At the current price of $99.02, the stock is -8.4% from its 52-week high of $108.14. His prior five trades at BSX were all sells executed across 2024–2025, with a same-ticker timing pattern of 1 of 5 prior sells well-timed at the 90-day mark; the most recent prior sale on 2025-08-01 saw a 90-day return of -3.9% (well-timed), and the sale before that on 2025-05-01 returned +4.6% over 90 days (poorly timed). Cross-ticker, his seven prior sells averaged a 90d return of +6.1%, though his 90-day well-timed rate was only 14.29%. The fundamental backdrop shows BSX trading at a P/E of 52.67 with strong revenue growth of +17.6% year-over-year, suggesting the stock remains relatively valued despite recent near-term weakness.

Director Zane Ellen M sold 12,891 shares of BSX at $98.28 on 2025-11-06, reducing holdings by 34.8%.

Zane Ellen M, a Director, sold 12,891 shares (12.9K shares) at $98.28 on 2025-11-06, reducing her holdings from 37,025 shares (37.0K shares) to 24,134 shares (24.1K shares)—a 34.8% reduction in position size. The sale occurred within one week of two prior BSX sales (2025-10-28 and 2025-10-27), suggesting a coordinated reduction in holdings over a short timeframe. At the cross-ticker level, her prior three open-market sells showed average 90-day returns of +0.2% and a well-timed rate of 0.00%, indicating her historical sales have not captured downside timing—a pattern consistent with the prior BSX sale on 2025-02-24, which posted a +0.2% 90-day return. The stock currently trades at $99.05, just 1.2% above the sale price, within a 52-week range of $83.62–$108.14; the fundamental profile shows strong growth (+17.6% annual revenue growth) and profitability ($755.0M net income on $5.1B revenue), but a high P/E of 52.69 may reflect elevated valuation expectations.

EVP Cardiology Fitzgerald sells 50,000 shares (50.0K shares) for $4,973,337.63 across 3 transactions at BSX

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, executed 3 separate sales totaling 50,000 shares for $4,973,337.63 on November 3, 2025, reducing his holdings by 21.9% from 228,342 to 178,342 shares. The sales occurred at a blended average price of $99.47, slightly above the current price of $98.84, within the 52-week range of $83.62–$108.14. Fitzgerald's recent pattern at Boston Scientific shows 5 prior trades since August, predominantly sells, with mixed near-term outcomes: his prior 2 October sells posted 30-day gains of +2.4% and +1.8%, while his September sales showed 30-day declines of -9.1% and -8.3%. His cross-ticker track record across all tickers shows 12 prior sells with an average 90-day return of +3.7% and a 37.50% well-timed rate, indicating his recent sell patterns have not consistently preceded stock declines. This large concentrated reduction in a material position occurs without scheduled trading plan disclosure in the filing, though the magnitude and frequency of recent transactions warrant monitoring for strategic context.

Director Zane Ellen M sold 12,891 shares of BSX in 2 transactions (Oct 27-28) for $1,306,899.51, reducing stake by 34.8%

Zane Ellen M, a BSX director, executed 2 separate open-market sales totaling 12,891 shares for $1,306,899.51 on 2025-10-27 and 2025-10-28 at an average price of $101.38, reducing her holdings from 37,025 shares to 24,134 shares. The sales occurred near the 52-week high ($108.14), with the stock currently at $100.97, and came after a 30-day gain of +2.8%. Her cross-ticker track record shows a 0.00% well-timed sell rate across 1 prior sales, and at BSX specifically, her prior 2025-02-24 sale posted a 90-day return of +0.2%, indicating the stock rose after that sale. The current filing represents a material reduction in her position but lacks timing precision: her historical sells at this ticker have not preceded declines, and no 10b5-1 plan flag is noted, meaning this is discretionary activity. Investors should note the position reduction coincides with BSX trading near its recent highs, though her prior BSX sales have not demonstrated a pattern of anticipating weakness.

EVP of Cardiology sells 50,000 BSX shares in 2 transactions (8,245 @ $98.91, 41,755 @ $98.38) for $4,923,326.81

Fitzgerald Joseph Michael, EVP & Group Pres of Cardiology at Boston Scientific, executed 2 separate sales totaling 50,000 shares on 2025-10-01 for a blended average price of $98.47, reducing his holdings by -21.9% to 178,342 shares. The transaction occurred as the stock trades at $95.85, down -11.4% from its 52-week high of $108.14 and down -9.2% over the past 30 days. Across his open-market history at this ticker, his 5 prior trades show a 50% well-timed rate at the 90-day mark for sells (1 of 2 prior measurable sells were timed to precede declines), and his cross-ticker track record shows a 28.57% well-timed rate on sells, with most recent outcomes at BSX (two September sales) not yet measurable. The company fundamentals remain solid with $5.1B quarterly revenue and +17.6% annual revenue growth, though the elevated P/E of 56.72 and recent stock weakness merit observation alongside this substantial equity reduction by a division president.

BSX EVP Cardiology sells 50,000 shares at $104.89–$105.85 for $5.3M, reducing stake by 21.9% to 178.3K shares

Fitzgerald Joseph Michael, EVP & Group President of Cardiology, executed two separate sales totaling 50,000 shares for $5,271,416.44 on 2025-09-02 at blended average price $105.43—near the 52-week high of $107.76. This represents a 21.9% reduction in his holdings. His prior five trades at BSX show a mixed pattern: one of three measurable 90-day outcomes was well-timed, with the most recent sell on 2025-08-01 posting +0.8% in 30 days. The company trades at a P/E of 63.63 with annual revenue growth of +17.6% and $795.0M net income on $5.1B quarterly revenue. The current stock price ($107.53) has declined 0.2% from the 52-week high but risen 4.6% over 90 days and 0.7% over 30 days, indicating strength in the broader trend despite proximity to yearly highs.